A retrospective analysis of US medical records of people aged 65-95 years finds those with psoriasis on systemic therapies ...

Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.

For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers in blood, characterized by high-sensitivity C-reactive protein, despite ...

Discover a study in which researchers examined three international cohorts of patients with moderate-to-severe psoriasis ...

In adults with psoriasis, adding methotrexate to adalimumab did not improve effectiveness or drug survival compared with ...

The Emirates Dermatology Society recently organised a public awareness march at Al Safa Park in Dubai as part of its campaign ...

Adults with plaque psoriasis aged 65 years and older had similar responses to IL-17 and IL-23 inhibitors to that of younger adults.

Starjemza (ustekinumab-hmny) was approved by the FDA this week as a biosimilar to Stelara. 2 A pair of clinical trials ...

Innovent Biologics doses first participant in phase 3 clinical study of picankibart: San Francisco Friday, May 30, 2025, 12:00 Hrs [IST] Innovent Biologics, Inc, a world-class bio ...

Treatment Market is set to acquire a value of USD 11,973.7 million in 2024. By 2034, the value of the psoriatic arthritis (PsA) treatment market is slated to shoot upwards of USD 25,375.6 million. As ...

8% of patients maintained that the ongoing war had affected the quality of the treatment they are receiving for psoriasis.

Currently, all biologic treatments for psoriasis, including anti-tumour necrosis factor therapies (anti-TNFs) and Stelara (ustekinumab) are recommended for second-line systemic therapy in Europe.